Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15202883 | 0.92 | SYK (0.64) | SYKSMN1; SMN2LMNAIDO1MAPT | |
| SCHEMBL19972926 | 0.89 | SYK (0.64) | SYKSMN1; SMN2LMNAIDO1MAPT | |
| SCHEMBL26773396 | 0.89 | MAPT (0.60) | SYKSMN1; SMN2LMNAIDO1MAPT | |
| SCHEMBL3478848 | 0.88 | MAPT (0.59) | SYKSMN1; SMN2LMNAIDO1MAPT | |
| SCHEMBL13480435 | 0.87 | MAPT (0.65) | SYKSMN1; SMN2LMNAIDO1MAPT | |
| SCHEMBL13938297 | 0.87 | HTT (0.65) | SYKSMN1; SMN2LMNAIDO1MAPT | |
| SCHEMBL12081968 | 0.86 | HTT (0.60) | SYKSMN1; SMN2LMNAIDO1MAPT | |
| SCHEMBL17753462 | 0.86 | MAPT (0.62) | SYKSMN1; SMN2LMNAIDO1MAPT | |
| SCHEMBL15679441 | 0.85 | MAPT (0.64) | SYKSMN1; SMN2LMNAIDO1MAPT | |
| SCHEMBL13090607 | 0.85 | MAPT (0.64) | SYKSMN1; SMN2LMNAIDO1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373929-A1 | FUSED RING DIIMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | XIANGBEI WELMAN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| EP-4215521-A1 | FUSED RING DIIMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Xiangbei Welman Pharmaceutical Co., Ltd (CN) | 2023-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373929-A1 | FUSED RING DIIMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | WEE1, CYP51A1, WEE2 | SYK 1039/4885SMN1; SMN2 4536/4885LMNA 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.